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OBJECTIVES We evaluated the ability of serum amyloid A (SAA), alone and in combination with a rapid
qualitative assay for cardiac-specific troponin T (cTnT), to predict 14-day mortality in
patients with unstable angina or non-Q wave myocardial infarction (NQMI).
BACKGROUND Elevated C-reactive protein (CRP) has been associated with adverse outcomes in unstable
coronary syndromes but data regarding its acute phase counterpart, SAA, are conflicting.
METHODS Serum amyloid A measurement and a rapid cTnT assay were performed on blood obtained
at enrollment into Thrombolysis in Myocardial Infarction 11A, a dose-ranging trial of
enoxaparin for unstable angina and NQMI.
RESULTS Serum amyloid A was higher in patients who died compared with survivors (6.28 vs.
0.75 mg/dL, p 5 0.002). Among patients with a negative rapid cTnT, mortality was higher
for those in the top quintile of SAA (6.1 vs. 0.7%, p 5 0.003). Patients with both an early
positive rapid cTnT (#10 min until assay positive) and SAA in the fifth quintile had the
highest mortality followed by those with either markedly elevated SAA or an early positive
rapid cTnT, while patients with both a negative rapid cTnT and SAA in quintiles 1–4 were
at very low risk, (9.1 vs. 3.6 vs. 0.7%, p ,0.002).
CONCLUSIONS Similar to CRP, baseline elevation of SAA identifies patients hospitalized with unstable
angina and NQMI at higher risk for early mortality, even among those with a negative rapid
assay for cTnT. These data support further investigation of inflammatory markers used alone
and in combination with cardiac troponins for risk assessment in unstable coronary
syndromes. (J Am Coll Cardiol 2000;35:358–62) © 2000 by the American College of
Cardiology
Serum cardiac markers provide diagnostic and prognostic
information that may refine our ability to manage the
heterogeneous population presenting with acute coronary
syndromes. Candidate markers reflect critical elements in-
volved in the evolution of an acute coronary syndrome (1).
With inflammation now recognized as contributing to
atherogenesis (2,3), inflammatory proteins have been inves-
tigated as potential indicators of underlying atherosclerosis
(4,5) as well as “unstable” atheromatous lesions (6–8).
Elevated levels of C-reactive protein (CRP), the prototyp-
ical acute phase protein, are associated with adverse cardio-
vascular outcomes in patients with stable (9) and unstable
ischemic heart disease (7–9), as well as healthy men without
clinical vascular disease (5). However, the specific mecha-
nism(s) underlying these associations between CRP and
prognosis are unclear, and thus researchers continue to
evaluate other inflammatory markers which might provide
consistent evidence of a correlation between systemic in-
flammation and cardiovascular risk (10,11).
Serum amyloid A (SAA), also an important acute phase
protein, has an expanded dynamic range with different
kinetics compared with CRP (12–14) and is reported to be
a more sensitive indicator of inflammation in some noncar-
diovascular inflammatory conditions (14,15). However,
SAA has not been examined as extensively in ischemic heart
disease (7,9,16) and prospective studies have shown con-
flicting results regarding prognosis (7,9,17). We have pre-
viously demonstrated the ability of CRP, alone and in
conjunction with a rapid bedside assay for cardiac-specific
troponin T (cTnT), to predict 14-day mortality in a cohort
of patients hospitalized with unstable angina or non-Q wave
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myocardial infarction (NQMI) (8). In this analysis, we now
evaluate whether a similar relationship exists between SAA
and clinical outcome in this population of patients present-
ing with non-ST elevation acute coronary syndromes.
METHODS
Patients. Men and women admitted with unstable angina
or NQMI and enrolled in Thrombolysis In Myocardial
Infarction (TIMI) 11A at any of the 45 participating centers
were eligible for the serum marker substudy. TIMI 11A was
an open-label dose ranging study of the low molecular
weight heparin, enoxaparin, in patients with evidence of
ischemic heart disease presenting with unstable angina or
NQMI within the prior week. Further details of the
inclusion criteria have been outlined previously (18). Pa-
tients with an evolving Q wave myocardial infarction (MI)
or thrombolytic therapy within 24 h before randomization,
coronary artery bypass surgery (CABG) within the previous
two months or other serious illness (active cancer, signifi-
cant hepatic or renal dysfunction) were excluded. Patients
received one of two weight-based doses of subcutaneous
enoxaparin plus aspirin administered in hospital for a
minimum of 48 h and then continued on a fixed dose of
enoxaparin subcutaneous Q12 h for a total treatment period
of two weeks, after which each patient’s clinical status was
ascertained (18).
Blood sampling and measurement of serum markers.
The serum marker protocol specified that a blood specimen
be drawn at enrollment for the determination of baseline
cardiac markers. The sera were stored at 220°C or colder
until shipped to a core laboratory (Clinical Chemistry
Laboratory, Children’s Hospital, Boston, Massachusetts)
where all samples were assayed by a single operator blinded
to patient treatment and outcome. Quantitative serum SAA
(N Latex SAA, Dade Behring, Newark, Delaware) deter-
mination was performed on the BN II Nephelometer (Dade
Behring, Newark, Delaware). The sensitivity of the assay is
0.08 mg/dL with variability at concentrations of 1.15 and
8.16 mg/dL of less than 7.3%. Quantitative CRP has been
previously measured using the N Latex CRP monoassay
(Dade Behring).
A rapid qualitative assay for cTnT was performed at
enrollment at each site. The intensity of the color and speed
with which a positive assay result develops correlates with
the concentration of cTnT in the patient’s blood (19). The
detection limit of this assay version is 0.2 ng/ml. The test
was read as either positive (red line appeared within 20 min)
or negative. Positive results were further categorized as to
whether the red line appeared in #10 min or .10 min with
an early positive result reflecting higher concentrations of
cTnT (20).
Statistical analysis. The SAA and cTnT data were merged
with the TIMI 11A clinical database and analyses per-
formed at COVANCE (Princeton, New Jersey). Complete
information regarding SAA and rapid cTnT status, includ-
ing the time to positivity of the rapid assay, were required
for inclusion in this substudy. Since prior data with cardiac
troponins have shown diminished sensitivity in patients
presenting less than 6 h after onset of ischemic symptoms,
patients who had enrollment specimens drawn earlier than
6 h after symptom onset were excluded. Statistical compar-
ison of baseline characteristics and clinical outcomes were
performed using the chi-square or Fisher exact test for
dichotomous variables and either the Wilcoxon rank sum or
two sample t test for continuous variables. Correlation
between baseline CRP and SAA was evaluated with a
Spearman rank test. All statistical comparisons were two-
tailed and p values of ,0.05 were considered to indicate
statistical significance.
RESULTS
Baseline characteristics. Of the 630 patients enrolled in
TIMI 11A, 435 (69%) had the requisite serum marker
information for this substudy. Those who did not have the
required data had lower rates of previously diagnosed
coronary artery disease (CAD) (63 vs. 74%) but did not
differ with respect to any traditional cardiovascular risk
factors including age, gender, smoking, cholesterol, hyper-
tension or diabetes.
Serum amyloid A values ranged from 0.09 to 80.9 mg/dL
with a median of 0.768 mg/dL and 25th and 75th percen-
tiles of 0.44 and 1.86 mg/dL, respectively. All patients with
baseline SAA concentrations in the fifth quintile had SAA
levels exceeding the 99th percentile of normal controls
(1.2 mg/dL) as previously established in the core laboratory
(21). A strong correlation between SAA and CRP levels at
baseline was observed (r 5 0.71, p 5 0.0001). Baseline
characteristics for the patients with markedly elevated SAA
were similar to those for the remainder of the population
with few exceptions as detailed in Table 1. It is not expected
that higher rates of intravenous heparin and nitroglycerin
use would have adversely effected mortality in this group.
Serum markers and mortality. All cause 14-day mortality
for the study population was 1.6%. Median SAA concen-
tration at enrollment was significantly elevated at 6.28 mg/
dL among those patients who subsequently died during the
14-day follow-up period versus 0.746 mg/dL among survi-
vors (p 5 0.002). Those with the highest levels of baseline
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359JACC Vol. 35, No. 2, 2000 Morrow et al.
February 2000:358–62 Serum Amyloid A in Acute Coronary Syndromes
SAA were at significantly increased mortality risk (Fig. 1).
Moreover, this relationship persisted among the 346 pa-
tients with negative rapid assays for cTnT (Fig. 1). In a risk
stratification scheme employing both SAA and rapid cTnT,
we found that patients with both an early positive rapid
cTnT assay (#10 min) and SAA in the fifth quintile were
at highest mortality risk. Whereas, those with either mark-
edly elevated SAA or an early positive rapid cTnT assay
were at intermediate risk compared with patients with both
a negative rapid cTnT assay and SAA in quintiles 1–4 who
were at very low mortality risk (p ,0.002; Fig. 2).
A markedly elevated SAA (Quintile 5) at baseline was a
more sensitive predictor of early mortality than either an
early positive cTnT assay or any positive rapid troponin
result (71% vs. 29% vs. 29%) while maintaining comparable
specificity (81% vs. 91% vs. 79%). The combination of a
markedly elevated SAA and an early positive rapid cTnT
assay was the most specific marker combination at 95% and
was associated with the highest likelihood ratio for mortality
at 5.6.
In an analysis of mortality stratified by CRP results
previously reported for this population (8), SAA did not
offer further prognostic information among those with
positive (mortality of 3.3% vs. 6.5% in SAA Q1–4 vs. Q5,
p 5 0.52) or negative CRP results. A positive CRP
identified a single patient in SAA Q1–4 who subsequently
died by 14 days, but the difference was not statistically
important with respect to mortality prediction (p 5 0.17).
The combination of a positive SAA and CRP was slightly
more specific for mortality prediction than SAA or CRP
alone (83% vs. 81% vs. 76%, respectively).
DISCUSSION
This analysis of serum markers drawn at enrollment of
patients with unstable angina and NQMI in TIMI 11A
suggests that, like its acute phase counterpart CRP, SAA
may provide important prognostic information with respect
to short term mortality among patients presenting with an
acute coronary syndrome without ST elevation. We found
that a markedly elevated SAA at enrollment is predictive of
increased mortality at 14 days even among those with a
negative assay for troponin. Further, we observed that the
combination this alternative marker of inflammation and
cardiac specific troponin data again yielded a comprehensive
approach to risk assessment.
Previous clinical studies. While a prognostic role for CRP
in unstable ischemic heart disease has now been demon-
strated in at least six prospective studies (7–9,22–24), the
data regarding a similar capacity of SAA are fewer and
conflicting (7,9,24). In a study of 31 patients presenting
with unstable angina without evidence of myocardial necro-
sis, those subjects with elevated SAA on admission had
more frequent recurrent angina and exhibited associated
trends toward higher rates of revascularization, MI and
death (7). In contrast, the European Concerted Action on
Thrombosis and Disabilities Study Group found that SAA
was not predictive of more frequent nonfatal MI or cardiac
death among 2,121 patients with angina followed prospec-
tively for two years (9). However, the population studied in
this long-term European study was recruited from outpa-
tient clinics and included patients with stable angina as well
as atypical chest pain and, thus, was very different from the
hospitalized population examined by Liuzzo and colleagues.
The prognostic capacity of SAA in patients with severe
unstable angina has been additionally supported by recent
data demonstrating an association between elevation of
SAA at discharge and higher rates of admission for recur-
rent unstable angina or MI by one year (24).
Potential implications. Our report extends prior observa-
tions for SAA to short term mortality in the acute hospital
setting and demonstrates the prognostic capacity of this
additional inflammatory marker used in combination with
cTnT. Further, we find that the sensitivity and specificity of
SAA as a predictor of early mortality compare favorably
with that observed previously in this population for CRP
(71 vs. 86% and 81 vs. 76%, respectively) (8). Though we
Table 1. Baseline Characteristics
Baseline Characteristic
SAA Quintiles
1–4
SAA Quintile
5
Age (yr)
N 348 87
Mean 62 64
Gender
Male 228 (66) 51 (59)
Female 120 36
Race
White 277 (80) 70 (80)
Other 71 17
Diabetes 114 (33) 31 (36)
Current smoker 94 (27) 22 (25)
Hypertension 212 (61) 52 (60)
Prior cardiac history
Angina 260 (75) 62 (71)
Prior angiogram with
stenosis $50%
203 (60) 48 (55)
PTCA 61 (18) 10 (12)
CABG 33 (10) 11 (13)
MI 5 (1) 2 (2)
Medications before
enrollment
ASA 287 (83) 79 (91)
Intravenous nitrates 83 (24) 41 (47)*
Beta-blocker 165 (47) 48 (55)
Intravenous heparin 177 (51) 58 (67)*
*Denotes categories for which p # 0.05. For continuous variables, values shown
indicate the median; for dichotomous variables, values indicate the number (percent)
of patients with a given finding.
ASA 5 aspirin; CABG 5 coronary artery bypass grafting; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty; SAA 5 serum
amyloid A.
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must recognize the limitations that stem from examining
this relationship in a single cohort with relatively few events,
our current analysis corroborates prior observations corre-
lating elevated SAA with adverse cardiovascular outcome
and supports further investigation of other inflammatory
markers in addition to CRP.
As the pathophysiologic relationship between elevation of
CRP and adverse clinical outcomes has remained undefined,
possible direct effects of CRP on coagulation and intracel-
lular adhesion have been raised (25,26). While the current
data demonstrating the predictive capacity of a second
inflammatory marker do not exclude the possibility of such
direct interactions of CRP or SAA, they suggest that the
observed prognostic associations may be more likely due to
a primary inflammatory process than to direct effects of
CRP or SAA. In addition, investigators have observed an
advantage of combined use of SAA and CRP to identify
individuals with consistent evidence of systemic inflamma-
Figure 1. Mortality at 14 days by SAA concentration in all patients and those with negative (neg) rapid cTnT assays. SAA 5 serum
amyloid A. SAA concentrations: open square 5 quintiles 1–4; closed square 5 quintile 5.
Figure 2. Risk stratification by SAA and rapid assay status expressed as 14-day mortality by SAA and rapid cTnT result. Early positive
rapid assays could be read positive by #10 minutes. cTnT 5 cardiac specific troponin T; Neg 5 negative; Pos 5 positive; Q 5 quintile;
SAA 5 serum amyloid A.
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tion in the prognostic evaluation of patients with stable
ischemic heart disease (17). Further investigation evaluating
the relative contributions of SAA and CRP, as well as the
combination of these acute phase proteins, in cardiovascular
risk assessment appears warranted.
Conclusions. This report supports the prognostic value of
baseline SAA measurement with respect to short term
mortality among patients presenting with non-ST elevation
acute coronary syndromes. Similar to CRP, SAA is found to
identify a population of patients without elevation of cTnT
who remain at increased mortality risk and thus confers
additional prognostic information beyond that provided by
troponin alone. The results of this study support further
investigation of markers of inflammation alone and in
combination with specific indicators of myocardial necrosis
for cardiovascular risk assessment in unstable ischemic heart
disease.
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